|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004927,
umls-concept:C0010171,
umls-concept:C0034656,
umls-concept:C0045093,
umls-concept:C0144576,
umls-concept:C0205179,
umls-concept:C0278996,
umls-concept:C0679729,
umls-concept:C1518578,
umls-concept:C1522690,
umls-concept:C2603343
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2006-9-28
|
|
pubmed:abstractText |
The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months. In the present randomized phase III trial we compared two new combinations containing new drugs with proven activity in phase II studies with patients with HNC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:AngouridakisNN,
pubmed-author:AravantinosGG,
pubmed-author:BafaloukosDD,
pubmed-author:BamiasAA,
pubmed-author:ChristodoulouCC,
pubmed-author:DafniUU,
pubmed-author:DaniilidisJJ,
pubmed-author:EconomopoulosTT,
pubmed-author:FountzilasGG,
pubmed-author:KalofonosHpH,
pubmed-author:Kalogera-FountzilaAA,
pubmed-author:KarinaMM,
pubmed-author:MakatsorisTT,
pubmed-author:ManiadakisNN,
pubmed-author:NikolaouAA,
pubmed-author:PapakostasPP,
pubmed-author:PavlidisNN,
pubmed-author:StathopoulosGG,
pubmed-author:SyrigosKK
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1560-7
|
|
pubmed:meshHeading |
pubmed-meshheading:16790517-Adult,
pubmed-meshheading:16790517-Aged,
pubmed-meshheading:16790517-Aged, 80 and over,
pubmed-meshheading:16790517-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16790517-Carcinoma, Squamous Cell,
pubmed-meshheading:16790517-Cost-Benefit Analysis,
pubmed-meshheading:16790517-Deoxycytidine,
pubmed-meshheading:16790517-Doxorubicin,
pubmed-meshheading:16790517-Female,
pubmed-meshheading:16790517-Greece,
pubmed-meshheading:16790517-Head and Neck Neoplasms,
pubmed-meshheading:16790517-Humans,
pubmed-meshheading:16790517-Male,
pubmed-meshheading:16790517-Middle Aged,
pubmed-meshheading:16790517-Paclitaxel,
pubmed-meshheading:16790517-Patient Compliance,
pubmed-meshheading:16790517-Polyethylene Glycols,
pubmed-meshheading:16790517-Survival Analysis,
pubmed-meshheading:16790517-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.
|
|
pubmed:affiliation |
Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Macedonia, Greece. fountzil@med.auth.gr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
